-
Product Insights
NewNeuroendocrine Tumors – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and...
-
Product Insights
NewFibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2024
Empower your strategies with our Fibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis, or lupus. Treatment includes pain relievers, antidepressants, and anti-seizure drugs. The Fibromyalgia (Fibromyalgia Syndrome) drugs in development market research report provide comprehensive information...
-
Product Insights
NewThalassemia – Drugs In Development, 2024
Empower your strategies with our Thalassemia – Drugs In Development, 2024 report and make more profitable business decisions. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite, and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant. The Thalassemia drugs in development market research report provide comprehensive information on the therapeutics under development for...
-
Product Insights
NewBeta Thalassaemia – Drugs In Development, 2024
Empower your strategies with our Beta Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions. Beta-thalassemia is a genetic blood disorder characterized by reduced or absent production of beta-globin chains, a component of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This deficiency leads to anemia and various complications. Beta-thalassemia is classified based on the severity of symptoms: In beta-thalassemia major (Cooley's anemia), individuals have little or no beta-globin production, leading...
-
Product Insights
NewNeuropathy – Drugs In Development, 2024
Empower your strategies with our Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions...
-
Product Insights
NewLiver Failure (Hepatic Insufficiency) – Drugs In Development, 2024
Empower your strategies with our Liver Failure (Hepatic Insufficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea, and loss of appetite. Since these symptoms are associated with...
-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...
-
Product Insights
NewAcquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024
Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into "warm" and "cold" types, depending on the...